Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Hayes Christopher G.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Hayes Christopher G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Goldenberg GaryOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Goldenberg GaryOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Kohler TerryOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Kohler TerryOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Bonaccorso JoeOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Bonaccorso JoeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:White TedOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:225,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:White TedOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
Filings by filing date
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Hayes Christopher G.Ownership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Hayes Christopher G.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Goldenberg GaryOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Goldenberg GaryOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Kohler TerryOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Kohler TerryOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Bonaccorso JoeOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Bonaccorso JoeOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:White TedOwnership Type:Direct OwnershipSecurities:Employee Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:225,000Price:--
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:White TedOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:112,500Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10 N High St Ste 200 WEST CHESTER PA 19380-3014 |
Tel: | N/A |
Website: | https://verrica.com |
IR: | See website |
Key People | ||
Ted W. White President, Chief Executive Officer, Director | P. Terence Kohler Chief Financial Officer | Christopher G. Hayes General Counsel, Company Secretary, Chief Legal Office |
Joe Bonaccorso Chief Commercial Officer | Gary Goldenberg Chief Medical Officer |
Business Overview |
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts. |
Financial Overview |
For the fiscal year ended 31 December 2023, Verrica Pharmaceuticals Inc revenues decreased 43% to $5.1M. Net loss increased from $24.5M to $67M. Revenues reflect Collaboration revenue decrease of 95% to $466K. Higher net loss reflects General and administrative - Balancing increase from $13.9M to $32M (expense), Stock-Based Compensation in SG&A increase from $3.5M to $11.8M (expense). |
Employees: | 100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $225.85M as of Dec 31, 2023 |
Annual revenue (TTM): | $5.12M as of Dec 31, 2023 |
EBITDA (TTM): | -$62.67M as of Dec 31, 2023 |
Net annual income (TTM): | -$67.00M as of Dec 31, 2023 |
Free cash flow (TTM): | -$38.94M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 42,418,553 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |